225 related articles for article (PubMed ID: 18369415)
1. Entropy measures quantify global splicing disorders in cancer.
Ritchie W; Granjeaud S; Puthier D; Gautheret D
PLoS Comput Biol; 2008 Mar; 4(3):e1000011. PubMed ID: 18369415
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic impact of transcript isoform switching in 1,209 cancer samples covering 27 cancer types using an isoform-specific interaction network.
Kahraman A; Karakulak T; Szklarczyk D; von Mering C
Sci Rep; 2020 Sep; 10(1):14453. PubMed ID: 32879328
[TBL] [Abstract][Full Text] [Related]
3. Splicing Regulators and Their Roles in Cancer Biology and Therapy.
da Silva MR; Moreira GA; Gonçalves da Silva RA; de Almeida Alves Barbosa É; Pais Siqueira R; Teixera RR; Almeida MR; Silva Júnior A; Fietto JL; Bressan GC
Biomed Res Int; 2015; 2015():150514. PubMed ID: 26273588
[TBL] [Abstract][Full Text] [Related]
4. Alternative transcription and alternative splicing in cancer.
Pal S; Gupta R; Davuluri RV
Pharmacol Ther; 2012 Dec; 136(3):283-94. PubMed ID: 22909788
[TBL] [Abstract][Full Text] [Related]
5. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
Bessa C; Matos P; Jordan P; Gonçalves V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
[TBL] [Abstract][Full Text] [Related]
6. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract][Full Text] [Related]
7. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
8. Cryptic splice site activation during RNA processing of MLL/AF4 chimeric transcripts in infants with t(4;11) positive ALL.
Divoky V; Trka JM; Watzinger F; Lion T
Gene; 2000 Apr; 247(1-2):111-8. PubMed ID: 10773450
[TBL] [Abstract][Full Text] [Related]
9. [Pre-mRNA alternative splicing in cancer: functional impact, molecular mechanisms and therapeutic perspectives].
Revil T; Shkreta L; Chabot B
Bull Cancer; 2006 Sep; 93(9):909-19. PubMed ID: 16980234
[TBL] [Abstract][Full Text] [Related]
10. Splice variants as cancer biomarkers.
Brinkman BM
Clin Biochem; 2004 Jul; 37(7):584-94. PubMed ID: 15234240
[TBL] [Abstract][Full Text] [Related]
11. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
12. Caffeine regulates alternative splicing in a subset of cancer-associated genes: a role for SC35.
Shi J; Hu Z; Pabon K; Scotto KW
Mol Cell Biol; 2008 Jan; 28(2):883-95. PubMed ID: 18025108
[TBL] [Abstract][Full Text] [Related]
13. AltTrans: transcript pattern variants annotated for both alternative splicing and alternative polyadenylation.
Le Texier V; Riethoven JJ; Kumanduri V; Gopalakrishnan C; Lopez F; Gautheret D; Thanaraj TA
BMC Bioinformatics; 2006 Mar; 7():169. PubMed ID: 16556303
[TBL] [Abstract][Full Text] [Related]
14. The contribution of alternative splicing to genetic risk for psychiatric disorders.
Reble E; Dineen A; Barr CL
Genes Brain Behav; 2018 Mar; 17(3):e12430. PubMed ID: 29052934
[TBL] [Abstract][Full Text] [Related]
15. Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study.
Montalban G; Fraile-Bethencourt E; López-Perolio I; Pérez-Segura P; Infante M; Durán M; Alonso-Cerezo MC; López-Fernández A; Diez O; de la Hoya M; Velasco EA; Gutiérrez-Enríquez S
Hum Mutat; 2018 Sep; 39(9):1155-1160. PubMed ID: 29969168
[TBL] [Abstract][Full Text] [Related]
16. Innovations in proteomic profiling of cancers: alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology.
Omenn GS; Menon R; Zhang Y
J Proteomics; 2013 Sep; 90():28-37. PubMed ID: 23603631
[TBL] [Abstract][Full Text] [Related]
17. Splice Expression Variation Analysis (SEVA) for inter-tumor heterogeneity of gene isoform usage in cancer.
Afsari B; Guo T; Considine M; Florea L; Kagohara LT; Stein-O'Brien GL; Kelley D; Flam E; Zambo KD; Ha PK; Geman D; Ochs MF; Califano JA; Gaykalova DA; Favorov AV; Fertig EJ
Bioinformatics; 2018 Jun; 34(11):1859-1867. PubMed ID: 29342249
[TBL] [Abstract][Full Text] [Related]
18. Alternative and aberrant splicing of MDM2 mRNA in human cancer.
Bartel F; Taubert H; Harris LC
Cancer Cell; 2002 Jul; 2(1):9-15. PubMed ID: 12150820
[TBL] [Abstract][Full Text] [Related]
19. Real-Time PCR Assay for the Analysis of Alternative Splicing of Immune Mediators in Cancer.
Wang R; Hossain MF; Mirkovic J; Sabzanov S; Ruggiu M
Methods Mol Biol; 2020; 2108():241-258. PubMed ID: 31939186
[TBL] [Abstract][Full Text] [Related]
20. Alternative splicing related genetic variants contribute to bladder cancer risk.
Guo Z; Zhu H; Xu W; Wang X; Liu H; Wu Y; Wang M; Chu H; Zhang Z
Mol Carcinog; 2020 Aug; 59(8):923-929. PubMed ID: 32339354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
